Last reviewed · How we verify
Chemodenervation (4 months)
Chemodenervation uses botulinum toxin to temporarily paralyze muscles by blocking acetylcholine release at the neuromuscular junction.
Chemodenervation uses botulinum toxin to temporarily paralyze muscles by blocking acetylcholine release at the neuromuscular junction. Used for Muscle spasticity and hypertonicity, Dystonia, Migraine prophylaxis.
At a glance
| Generic name | Chemodenervation (4 months) |
|---|---|
| Also known as | onabotulinumtoxin A, Botox, incobotulinumtoxin A, Xeomin |
| Sponsor | University of Wisconsin, Madison |
| Drug class | Botulinum toxin |
| Target | SNARE complex (synaptobrevin, SNAP-25, syntaxin) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Dermatology, Rehabilitation Medicine |
| Phase | FDA-approved |
Mechanism of action
Botulinum toxin cleaves SNARE proteins required for acetylcholine vesicle release, preventing muscle contraction. The effect is temporary, lasting approximately 3–4 months, after which neuromuscular function gradually recovers as new nerve terminals form. This mechanism is exploited therapeutically to reduce muscle hyperactivity in various conditions.
Approved indications
- Muscle spasticity and hypertonicity
- Dystonia
- Migraine prophylaxis
- Hyperhidrosis
- Cosmetic applications
Common side effects
- Muscle weakness or paralysis at injection site
- Headache
- Injection site pain or bruising
- Flu-like symptoms
- Antibody formation (reduced efficacy over time)
Key clinical trials
- Different Transcutaneous Electrical Nerve Stimulation Modes in Pudendal Neuralgia Post-prostatectomy (NA)
- A Prospective Controlled Treatment Trial for Post-Traumatic Headaches (PHASE3)
- Assessment of Growth Factors Levels Associated with Wound Healing After Soft Tissue Crown Lengthening (PHASE2)
- Intrathecal Morphine vs. Intrathecal Morphine and Regional Anesthesia After Cesarean Section. (PHASE4)
- Botulinum Toxin for Chronic Neuropathic Pain
- Amitriptyline vs GON and SON Blocks in Migraine (NA)
- Mixed Methods Investigation of Chronic Facial Paralysis in Individuals With Synkinesis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |